Crohn's disease

Sandoz launches Hyrimoz® (adalimumab) high-concentration formulation in Europe, aiming to improve patient care

Retrieved on: 
Tuesday, November 21, 2023
Rheumatoid arthritis, Crohn's disease, Novartis, Rheumatology, Patient, HCF, Adalimumab, Psoriasis, Medicine, Injection, Endocrinology, Uveitis, Ulcerative colitis, Pharmaceutical industry

The HCF formulation is administered with the familiar Hyrimoz® SensoReady® pen, aiming for an enhanced yet familiar patient experience.

Key Points: 
  • The HCF formulation is administered with the familiar Hyrimoz® SensoReady® pen, aiming for an enhanced yet familiar patient experience.
  • The launch of Hyrimoz ® HCF strengthens the Sandoz biosimilar portfolio in immunology, including Erelzi® (biosimilar etanercept), Zessly® (biosimilar infliximab) and Rixathon® (biosimilar rituximab, including rheumatoid arthritis indication).
  • Sandoz is committed to helping millions of patients access critical and potentially life-changing biologic medicines sustainably and affordably across a range of areas including immunology, oncology, supportive care, and endocrinology.
  • It has a leading global portfolio with eight marketed biosimilars and a further 25 assets in various stages of development.

ALPCO Announces the Commercial Launch of its FDA 510(k) Cleared Calprotectin Immunoturbidimetric Assay

Retrieved on: 
Tuesday, December 19, 2023
IBD, IBS, Crohn's disease, FDA, Calprotectin, Inflammatory bowel disease, UC, Hospital, Irritable bowel syndrome, Patient, Automation, Ulcerative colitis, Asset management

SALEM, N.H., Dec. 19, 2023 /PRNewswire/ -- American Laboratory Products Company, Ltd. ("ALPCO"), a global provider of specialty diagnostic solutions, proudly announces the commercial launch of its FDA 510(k) cleared Calprotectin Immunoturbidimetric Assay, enhancing its suite of Gastrointestinal (GI) diagnostic solutions.

Key Points: 
  • SALEM, N.H., Dec. 19, 2023 /PRNewswire/ -- American Laboratory Products Company, Ltd. ("ALPCO"), a global provider of specialty diagnostic solutions, proudly announces the commercial launch of its FDA 510(k) cleared Calprotectin Immunoturbidimetric Assay, enhancing its suite of Gastrointestinal (GI) diagnostic solutions.
  • The new Calprotectin Immunoturbidimetric Assay is a strategic addition to ALPCO's comprehensive GI solutions menu.
  • In July 2023, ALPCO unveiled the Calprotectin Immunoturbidimetric Assay at the American Association for Clinical Chemistry (now ADLM) annual meeting.
  • ALPCO has always been dedicated to blending the benefits of automation with expertise in immunoassays, a commitment that is exemplified in the Calprotectin Immunoturbidimetric Assay.

IMIDomics and Bristol Myers Squibb Expand Long-Standing Partnership to Advance Immune-Mediated Inflammatory Disease Treatment Research and Development

Retrieved on: 
Wednesday, December 6, 2023
Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Infectious Diseases, Clinical Trials, BMS, Ulcerative colitis, Crohn's disease, Atopic dermatitis, Psoriasis, Bristol Myers Squibb, IMID, Patient, Immune-mediated inflammatory diseases, Immunotherapy, Rheumatoid arthritis, Partnership, Pharmaceutical industry

This expanded partnership extends the existing relationship between the two companies, advancing their shared commitment to accelerate research and development aimed at treating IMID patients.

Key Points: 
  • This expanded partnership extends the existing relationship between the two companies, advancing their shared commitment to accelerate research and development aimed at treating IMID patients.
  • This strategic collaboration has continued to provide Bristol Myers Squibb with comprehensive insight into the clinical and molecular underpinnings of IMIDs.
  • Under this expanded collaboration, Bristol Myers Squibb and IMIDomics will partner to collect clinical and epidemiological data from patients with Sjögren's disease and atopic dermatitis, generating cutting-edge biomolecular data.
  • By tapping IMIDomics’ unique clinical network and resources, Bristol Myers Squibb and IMIDomics can select the right drug for the right patient at the right time.

Teva Completes Closing of Exclusive Collaboration Deal to Deliver Inflammatory Bowel Disease Treatment

Retrieved on: 
Thursday, November 30, 2023
Health, Other Science, General Health, Research, Science, Pharmaceutical, Biotechnology, NYSE, SAN, Teva Pharmaceuticals, Weight loss, Abdominal pain, Teva, Fatigue, TEVA, Ulcerative colitis, Crohn's disease, Inflammation, GI, IBD, Diarrhea, TEV, Inflammatory bowel disease, TASE, Medication, Sanofi

Inflammatory bowel disease (IBD) is the term for two conditions -- Crohn’s disease and ulcerative colitis – characterized by chronic inflammation of the gastrointestinal (GI) tract. Prolonged inflammation results in damage to the GI tract. The common symptoms for both conditions are persistent diarrhea, rectal bleeding, abdominal pain, fatigue, and weight loss. An estimated ~10 million people worldwide live with IBD.

Key Points: 
  • Teva Pharmaceuticals, a U.S. subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today closing of its collaboration deal to co-develop and co-commercialize asset TEV ‘574 with Sanofi (EURONEXT: SAN and NASDAQ: SNY).
  • TEV '574 is currently in Phase 2b clinical trials for the treatment of ulcerative colitis and Crohn's disease, two types of inflammatory bowel disease.
  • As announced on October 4th, 2023, under the terms of the agreement, Teva will receive an upfront payment of $500 million shortly after closing and up to $1 billion in development and launch milestones.
  • Inflammatory bowel disease (IBD) is the term for two conditions -- Crohn’s disease and ulcerative colitis – characterized by chronic inflammation of the gastrointestinal (GI) tract.

Ustekinumab (Stelara) by Janssen Biotech Biosimilars Pipeline Review 2023: Information on Approved Drugs and Drug Candidates in Research and Development as Biosimilar Antibodies

Retrieved on: 
Friday, December 15, 2023
INN, Psoriasis, Patient, Home, Ulcerative colitis, Crohn's disease, Interleukin, Abstract, Light, Janssen Pharmaceuticals, Ustekinumab

DUBLIN , Dec. 14, 2023 /PRNewswire/ -- The "Ustekinumab (Stelara) Biosimilars Pipeline Review" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN , Dec. 14, 2023 /PRNewswire/ -- The "Ustekinumab (Stelara) Biosimilars Pipeline Review" report has been added to ResearchAndMarkets.com's offering.
  • Stelara was approved in the US and EU in 2009.
  • Competitors described in a tabular format covering drug code/INN, target(s)/MoA, class of compound, territory of main competitor, indication(s) & R&D stage.
  • Project History with link to source of information (press release, homepage, abstracts, presentations, annual reports etc).

Intoleran Prioritizes a Clean Digestive Enzyme Manufacturing Process

Retrieved on: 
Thursday, November 30, 2023
Enzyme, Starch, Digestion, HPMC, Research, Stomach, American Gastroenterological Association, Bloating, Fructose, Food intolerance, Crohn's disease, Calcium carbonate, Lactase, Nausea, Lactose, Extrapyramidal system, Animal feed, Dairy

FORT LAUDERDALE, Fla., Nov. 30, 2023 /PRNewswire/ -- There are many reasons an individual might struggle with digestive concerns. In 2022, the American Gastroenterological Association (AGA) reported new research revealing that as much as 40% of Americans suffer from "digestive troubles" on a daily basis. At times, this can be severe and can stem from serious medical concerns, such as celiac disease or Crohn's disease.

Key Points: 
  • "Food intolerance is typically a lack of digestive enzymes in the body," explains Harmen Treep, owner of Intoleran.
  • However, to be effective, enzymes must be clean and should not contain ingredients that complicate digestive issues.
  • "If a digestive enzyme comes with a lengthy ingredients list on the bottle, think twice," Treep warns.
  • The Intoleran owner uses his brand's lactase 10,000 digestive enzyme capsules as an example.

Local Infusion Leverages Technology to Redefine Infusion Care, Secures $10 million Series A Funding Led by Blisce to Hire Leadership Team and Expand Geographic Footprint

Retrieved on: 
Wednesday, November 29, 2023
Practitioner, Patient satisfaction, RNS, Patient, Rheumatoid arthritis, General partnership, Marketing, Crohn's disease, Multiple sclerosis, Medicine, Growth, Physician, Health, Medical device, Nursing

NASHVILLE, Tenn., Nov. 29, 2023 /PRNewswire-PRWeb/ -- Local Infusion, the leading tech enabled infusion provider, announced it has closed on a $10 million Series A funding round led by Blisce with participation from Meridian Street Capital and existing investors. The new funds will be used to expand the company's footprint to New Jersey, Connecticut, and Maryland in 2024 and build out the company's proprietary referral and care coordination technologies.

Key Points: 
  • Local Infusion has grown rapidly in the last year, opening its first center last December to now operating four locations in the Northeast.
  • The company is the trusted infusion therapy provider for over 220 physicians, and has partnered with payors and employers to cover more than 1.3 million lives.
  • Local Infusion delivers comprehensive value-based care and infusion therapy to patients with chronic autoimmune diseases on specialty medications.
  • "Infusion care remains one the last segments in healthcare where Value Based Care has yet to fully take hold.

Aeglea BioTherapeutics Announces Name Change to Spyre Therapeutics, Appoints CEO and Additional Directors, and Expands Leadership Team to Develop Next-Generation Therapeutic Combinations for the Treatment of IBD

Retrieved on: 
Monday, November 27, 2023
JD, Pfizer, Acquisition, Engineering, CFO, Patient, FIH, Novartis, Growth, Doctor of Philosophy, Risankizumab, DevOps, Drug discovery, SYRE, Genentech, Spark Therapeutics, Corporation, Johnson & Johnson, Therapy, TL1A, SVP, Intellectual property, Ustekinumab, Inflammatory bowel disease, Disease, Medicine, FDA, Crohn's disease, IBD, MD, Mirati Therapeutics, CMC, Pharmaceutical industry, Management, Vaccine, Michael Spyres, Burrill Bernard Crohn

WALTHAM, Mass., Nov. 27, 2023 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE) (the "Company" or "Spyre"), a development-stage biotechnology company, today announced its name change to Spyre Therapeutics, Inc. Effective as of market open on November 28, 2023, Spyre will trade on Nasdaq under the ticker symbol "SYRE". The name change follows the acquisition of privately held Spyre Therapeutics, Inc. by the Company in June of 2023. Named to reflect the Company's ambition to achieve new heights in efficacy and convenience of Inflammatory Bowel Disease (IBD) therapies, Spyre aims to create a next-generation of IBD products by combining best-in-class antibody engineering, rational therapeutic combinations, and precision patient selection approaches to enhance efficacy for patients.

Key Points: 
  • Effective as of market open on November 28, 2023, Spyre will trade on Nasdaq under the ticker symbol "SYRE".
  • The name change follows the acquisition of privately held Spyre Therapeutics, Inc. by the Company in June of 2023.
  • The Company also announced today the appointment of Cameron Turtle, DPhil as Chief Executive Officer (CEO) and member of the Board of Directors.
  • SPY001 is currently progressing through IND-enabling studies and is expected to enter first-in-human ("FIH") studies in the first half of 2024.

Top Gastroenterology and Liver Disease Specialist, Dr. David P. Yamini, Receives Castle Connolly's 2023 Top Doctor® Award

Retrieved on: 
Thursday, November 9, 2023
Hepatology, Irritable bowel syndrome, Disorder, American Gastroenterological Association, Stomach, Esophagus, ERCP, IBS, Liver, American College of Gastroenterology, Liver disease, Internal medicine, Indigestion, Patient, Multimedia, Gastrointestinal Endoscopy, Human, Santa Monica Boulevard, Castle Connolly Medical, Cedars-Sinai Medical Center, Pancreas, American College, Ulcerative colitis, Gallbladder, Crohn's disease, Gastroenterology, University, SIBO, Physician, Inflammatory bowel disease, Castle, Nursing, Film industry

BEVERLY HILLS, Calif., Nov. 9, 2023 /PRNewswire-PRWeb/ -- Dr. David Yamini has been selected as a 2023 Top Doctor® by Castle Connolly. Dr. Yamini is an accomplished physician who is double board-certified in gastroenterology and internal medicine. He serves patients in Santa Monica and Beverly Hills, CA, treating diseases and disorders of the digestive system. Dr. Yamini's medical education, training, hospital appointments and disciplinary history were rigorously screened by the Castle Connolly physician-led research team. Castle Connolly publishes its list of Top Doctors at http://www.castleconnolly.com and in a wide variety of partner publications, magazines and affiliate websites. Around 7% of the nation's top board-certified, licensed physicians have been selected as Castle Connolly Top Doctors in their regions for their specialties. Individuals do not and cannot pay to be selected as a Castle Connolly Top Doctor. Dr. David Yamini offers advanced diagnostic and therapeutic procedures and has established a reputation as one of the best Los Angeles gastroenterologists and liver disease specialists. Dr. Yamini offers expertise in issues involving the digestive tract, biliary system, liver and pancreas, with a proficiency in endoscopic retrograde cholangiopancreatography (ERCP). He takes a comprehensive approach to diagnosing and treating patients with all types of gastrointestinal (GI) problems and disorders that affect the small and large intestine, stomach, esophagus, gallbladder, liver and pancreas, including inflammatory bowel disease (Crohn's, ulcerative colitis), indigestion (dyspepsia), small intestinal bacterial overgrowth (SIBO) and irritable bowel syndrome (IBS). Dr. Yamini provides his patients with a superior level of compassionate and attentive personalized care.

Key Points: 
  • BEVERLY HILLS, Calif., Nov. 9, 2023 /PRNewswire-PRWeb/ -- Dr. David Yamini has been selected as a 2023 Top Doctor® by Castle Connolly.
  • Dr. Yamini's medical education, training, hospital appointments and disciplinary history were rigorously screened by the Castle Connolly physician-led research team.
  • Dr. David Yamini offers advanced diagnostic and therapeutic procedures and has established a reputation as one of the best Los Angeles gastroenterologists and liver disease specialists .
  • "It is such an honor to be recognized by my peers for this award," says Dr. David Yamini.

Blackbird Labs, a Next-Generation Life Sciences Accelerator, Launches with $100 Million and Foundational Collaboration with Johns Hopkins University

Retrieved on: 
Tuesday, November 7, 2023
UMB, Colitis, DSM-IV codes, History of the University of Maryland, College Park, Innovation, Crohn's disease, Johns Hopkins University, RNA, Johns Hopkins, Biotechnology, Laboratory, University of Maryland, College Park, Research, Inflammation, RA, Lieber Institute for Brain Development, Drug development, Senior, Scripps Research, Clinical trial, Economic development, Ecosystem, Schizophrenia, Messenger, University, Senior advisor, Cancer, Entrepreneurship, Economy, Patient, Pharmaceutical industry, Management

BALTIMORE, Nov. 7, 2023 /PRNewswire/ -- Blackbird Laboratories, Inc. ("Blackbird Labs"), a next-generation life sciences accelerator, today announced that it has launched with a $100 million founding grant from The Stephen and Renee Bisciotti Foundation and research collaborations with Johns Hopkins University, the University of Maryland, Baltimore, and the Lieber Institute for Brain Development. Blackbird Labs' mission is to accelerate the development and commercialization of novel medicines and cutting-edge technologies to enhance the well-being of patients facing unmet medical needs.   

Key Points: 
  • Blackbird Labs provides capital, program management, and strategic scientific and business input from its newly recruited team of life sciences professionals, seeking to bridge the gap between pioneering academic science and industry.
  • Blackbird Labs is led by Matt Tremblay, Ph.D., the CEO and a founding member of the board of directors since Blackbird Labs' creation in January 2023.
  • Blackbird Labs launches with a world-class group of advisors spanning the global life sciences venture investment community and business leaders.
  • "Blackbird Labs is an exciting new element of our innovation ecosystem, a unique resource for funding and expertise to help bring Johns Hopkins technologies to market.